Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management
- 1 June 2000
- journal article
- review article
- Published by Elsevier BV in American Journal of Kidney Diseases
- Vol. 35 (6), 1226-1237
- https://doi.org/10.1016/s0272-6386(00)70064-3
Abstract
Hyperphosphatemia is a predictable consequence of chronic renal failure and is present in most patients on dialysis. Traditionally, the risk associated with elevated serum phosphorus has focused on its impact on renal osteodystrophy. A growing body of evidence, however, suggests that abnormalities in serum phosphorus, calcium-phosphorus product (CaxP), and parathyroid hormone (PTH) levels are resulting in vascular and visceral calcification, thereby contributing to the substantially increased risk of cardiovascular death in this population. In this analysis, we review in detail the literature that describes these associations. We show that the current treatment paradigm for serum phosphorus and secondary hyperparathyroidism is ineffective for a large segment of dialysis patients. Currently, 60% of hemodialysis patients have phosphorus greater than 5.5 mg/dL, and 40% have CaxP greater than 60 mg2/dL2. It is our belief that prevention of uremic calcification, cardiac death, and vascular disease should assume primary importance when evaluating the risks associated with elevated levels of phosphorus, CaxP, and PTH. We recommend that target levels should become 9.2 to 9.6 mg/dL for calcium, 2.5 to 5.5 mg/dL for phosphorus, less than 55 mg2/dL2 for CaxP product, and 100 to 200 pg/mL for intact PTH.Keywords
This publication has 70 references indexed in Scilit:
- Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of haemodialysis patients*Nephrology Dialysis Transplantation, 1999
- Cardiovascular Structural Changes in Uremia: Implications for Cardiovascular FunctionSeminars in Dialysis, 1999
- Phosphate-binding capacity of ferrihydrite versus calcium acetate in ratsAmerican Journal of Kidney Diseases, 1999
- Management of Hyperphosphatemia with Calcium‐Based BindersSeminars in Dialysis, 1999
- Vitamin D analoguesAmerican Journal of Kidney Diseases, 1998
- Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidismKidney International, 1997
- Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failureAmerican Journal of Kidney Diseases, 1996
- A clinical approach to the uraemic patient with extraskeletal calcificationsNephrology Dialysis Transplantation, 1996
- Effect of hematocrit on solute removal during high efficiency hemodialysisKidney International, 1990
- On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dogJCI Insight, 1971